CN102603740A - Synthetic method of 4-nitro-7-azaindole - Google Patents
Synthetic method of 4-nitro-7-azaindole Download PDFInfo
- Publication number
- CN102603740A CN102603740A CN2012100513821A CN201210051382A CN102603740A CN 102603740 A CN102603740 A CN 102603740A CN 2012100513821 A CN2012100513821 A CN 2012100513821A CN 201210051382 A CN201210051382 A CN 201210051382A CN 102603740 A CN102603740 A CN 102603740A
- Authority
- CN
- China
- Prior art keywords
- preparation
- compound
- acid
- reaction
- azaindole
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Abstract
The invention relates to the field of synthesis of medicament intermediates, in particular to a synthetic method of 4-nitro-7-azaindole. A preparation method disclosed by the invention is characterized by comprising the following steps of: I, reacting 1H-pyrrolo[2,3-b]pyridine-3-carbosylate serving as a raw material with m-chloroperoxybenzoic acid to obtain a compound VII; II, undergoing a nitration reaction to obtain a compound VIII; III, performing decarboxylation under the condition of dilute sulfuric acid to obtain a compound IV; and IV, removing an N-oxide under the action of PCl3 to obtain a compound I. The preparation method disclosed by the invention has the advantages of mild reaction conditions, high yield in each step, easiness for post-treatment, easiness for operating and suitability for industrial mass production.
Description
Technical field
The present invention relates to the synthetic field of pharmaceutical intermediate, be specifically related to the compound method of 4-nitro-7-azaindole.
Background technology
4-nitro-7-azaindole is a kind of very useful pharmaceutical intermediate.Be applied to recently in the synthetic nucleosides compounds, the nucleosides in the nucleic acid is formed with ribose or ribodesose condensation by (N1) of 4-nitro-7-azaindole or 4-amino-7-azaindole.Novel nucleoside compound has antiviral activity, is used to prepare antiviral, so 4-nitro-7-azaindole will be very crucial midbody.
For 4-nitro-7-azaindole preparation, bibliographical information related compound method is following:
Method is by J.Med.Chem.1982, and 25, the 1258-1261 report,
Reagent and productive rate: (a) metachloroperbenzoic acid (m-CPBA), methylene dichloride (DCM), 60%; (b) trifluoroacetic acid (TFA), nitrosonitric acid, 60%; (c) phosphorus trichloride, ETHYLE ACETATE, 80%.
Not enough below the compound method of this report exists: intermediate compound IV is difficult to the feasibility that shortcomings such as separation and purification, overall yield be low do not possess mass preparation because of there being isomer V.
Summary of the invention
The purpose of this invention is to provide a kind of efficient, compound method of possessing 4-nitro-7-azaindole that mass preparation is worth.Solve mainly that existing the 4-nitro-7-azaindole yield is low, midbody is difficult to purifying, can't scale operation etc. technical problem.
Preparing method of the present invention is a raw material with 1H-pyrrolo-[2,3-b] pyridine-3-carboxylic acid methyl esters, obtains compound VI I with the metachloroperbenzoic acid reaction; Second step obtained compound VIII through nitration reaction; The 3rd one-step hydrolysis decarboxylation obtains compound IV; The 4th step is at PCl
3Effect is taken off the N-oxide compound down, obtains compound I.
Reaction formula is following:
Reaction conditions: d wherein: oxidation; E: nitrated; F: hydrolysis decarboxylation; G: with PCl
3Reaction.
The preferred metachloroperbenzoic acid of the used oxygenant of oxidation step.Temperature of reaction can be carried out at normal temperatures, preferred 0～30 ℃.
Nitration reaction is preferably under the nitration mixture condition, to carry out, preferred 65～90 ℃ of temperature of reaction.
Said nitration mixture preferably in the vitriol oil or trifluoroacetic acid a kind of be selected from a kind of mixture in concentrated nitric acid or the nitrosonitric acid.Compound VI I wherein: the mol ratio of concentrated nitric acid or nitrosonitric acid is 1: 2～1: 7.
Preferred dilute sulphuric acid or the concentrated hydrochloric acid of adding in the hydrolysis decarboxylation step.The concentration of dilute sulphuric acid is preferred 10%～50%, is weight percentage.Compound VIII: the mol ratio of dilute sulphuric acid or concentrated hydrochloric acid is 1: 4～1: 7.Preferred 70～100 ℃ of hydrolysis decarboxylation temperature of reaction.
G step reaction temperature room temperature gets final product, and also can be 0～74 ℃, preferred 10～30 ℃.
Preparing method's reaction conditions of the present invention is relatively gentleer, and per step productive rate is all than higher, and total recovery can reach about 60%.And aftertreatment is simple, and is easy to operate, is fit to industrialized production.
Embodiment
Embodiment 1
Compound VI I's is synthetic
In the 25L reaction flask, and adding compound VI 1100g (6.25mol, 1.0eq), 15L EA; Lower the temperature 0 ℃, add in batches 2000g m-CPBA (8.11mol, 1.30eq), stirred overnight at room temperature; The LC-MS monitoring reaction is complete, filters, and the EA washing obtains compound VI I 1100g, yield 91%.
1H?NMR(400MHz，DMSO-d6)：8.21(d，1H)，8.12(s，1H)，7.92(d，1H)，7.22(d，1H)，3.82(s，1H)。
Synthesizing of compound VIII
The 10L four-hole bottle, and adding compound VI I 550g (2.86mol, 1.0eq), vitriol oil 1.5L, 70-80 ℃ of reaction of concentrated nitric acid 1L heating 1.5h, after reacting completely, reaction solution is poured in the frozen water, separates out a large amount of solids, filters, and directly carries out next step.
1HNMR?(400MHz，DMSO-d6)：8.41(d，1H)，8.30(s，1H)，7.85(d，1H)，3.57(s，3H)。
Synthesizing of compound IV
The 10L four-hole bottle, and adding compound VIII 600g (2.53mol, 1.0eq), dilute sulphuric acid 5L; Reflux, venting in a large number produces yellow solid in the heat-processed, and the back of refluxing is complete dissolves; Behind the back flow reaction 3h, react completely, reaction solution is cooled to-10 ℃; Ammoniacal liquor is regulated about PH to 4, separates out a large amount of yellow solids, and filtering drying gets compound IV yellow solid 374g.Two step yields: 73.2%.
1H?NMR(400MHz，DMSO-d6)：8.31(d，1H)，8.03(d，1H)，7.82(d，1H)，7.04(d，1H)。
Synthesizing of compound I
The 10L four-hole bottle adds EA 5L, and (4.019mol 1.0eq), stirs compound IV 720g, and solid can not dissolve entirely, and frozen water is cooled to 0 ℃, drips PCl
3(1269g, 9.24mol 2.3eq.), add the back and stir 30min, are warming up to 25 ℃ and stir 2h, react completely.Reaction solution is pounced in the ice, stirs, and separates out a large amount of solids, and strong aqua transfers PH greater than 4, filters, and the filter cake oven dry obtains glassy yellow solid 576.5g, yield: 88%, and purity: 99%.
1H?NMR(400MHz，DMSO-d)：12.58(s，1H)，8.51(d，1H)，7.96(dd，1H)，7.91(d，1H)，7.00(s，1H)。
Claims (9)
1. the preparation method of a compound (I) comprising:
Reaction conditions: d wherein: oxidation; E: nitrated; F: hydrolysis decarboxylation; G: with PCl
3Reaction.
2. the preparation method of claim 1, wherein the used oxygenant of oxidation step is a metachloroperbenzoic acid.
3. the preparation method of claim 1, wherein nitration reaction is under the nitration mixture condition, to carry out, 65～90 ℃ of temperature of reaction.
4. the preparation method of claim 3, wherein said nitration mixture be selected from the vitriol oil or the trifluoroacetic acid a kind of be selected from a kind of mixture in concentrated nitric acid or the nitrosonitric acid.
5. the preparation method of claim 3, wherein compound VI I: the mol ratio of concentrated nitric acid or nitrosonitric acid is 1: 2～1: 7.
6. the preparation method of claim 1, wherein the hydrolysis decarboxylation step adds dilute sulphuric acid or concentrated hydrochloric acid.
7. the preparation method of claim 6, wherein the concentration of dilute sulphuric acid is 10%～50%, is weight percentage.
8. the preparation method of claim 6, wherein compound VIII: the mol ratio of dilute sulphuric acid or concentrated hydrochloric acid is 1: 4～1: 7.
9. the preparation method of claim 1, wherein the hydrolysis decarboxylation temperature of reaction is 70～100 ℃.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210051382.1A CN102603740B (en) | 2012-03-01 | 2012-03-01 | Synthetic method of 4-nitro-7-azaindole |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210051382.1A CN102603740B (en) | 2012-03-01 | 2012-03-01 | Synthetic method of 4-nitro-7-azaindole |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102603740A true CN102603740A (en) | 2012-07-25 |
| CN102603740B CN102603740B (en) | 2014-05-14 |
Family
ID=46521570
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210051382.1A Active CN102603740B (en) | 2012-03-01 | 2012-03-01 | Synthetic method of 4-nitro-7-azaindole |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102603740B (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105777747A (en) * | 2016-04-05 | 2016-07-20 | 叶芳 | 4-chloro-7-azaindole and preparation method thereof |
| CN109694343A (en) * | 2018-12-19 | 2019-04-30 | 帕潘纳(北京)科技有限公司 | A kind of heterocyclic carboxylic acid class compound it is decarboxylation method used |
| CN112574095A (en) * | 2020-12-21 | 2021-03-30 | 常州大学 | Novel method for nitrifying isatin derivative |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004111048A1 (en) * | 2003-06-12 | 2004-12-23 | Sanofi-Aventis Deutschland Gmbh | 3-(guanidinocarbonyl)heterocycle derivatives, preparation process and intermediates of this process, their use as medicaments, and pharmaceutical compositions including them |
| WO2005058891A1 (en) * | 2003-12-09 | 2005-06-30 | Bayer Healthcare Ag | Pyrrolopyridine-substituted benzol derivatives for treating cardiovascular diseases |
| WO2005097790A1 (en) * | 2004-04-08 | 2005-10-20 | Bayer Healthcare Ag | Hetaryloxy-substituted phenylamino pyrimidines as rho kinase inhibitors |
-
2012
- 2012-03-01 CN CN201210051382.1A patent/CN102603740B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004111048A1 (en) * | 2003-06-12 | 2004-12-23 | Sanofi-Aventis Deutschland Gmbh | 3-(guanidinocarbonyl)heterocycle derivatives, preparation process and intermediates of this process, their use as medicaments, and pharmaceutical compositions including them |
| WO2005058891A1 (en) * | 2003-12-09 | 2005-06-30 | Bayer Healthcare Ag | Pyrrolopyridine-substituted benzol derivatives for treating cardiovascular diseases |
| WO2005097790A1 (en) * | 2004-04-08 | 2005-10-20 | Bayer Healthcare Ag | Hetaryloxy-substituted phenylamino pyrimidines as rho kinase inhibitors |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105777747A (en) * | 2016-04-05 | 2016-07-20 | 叶芳 | 4-chloro-7-azaindole and preparation method thereof |
| CN109694343A (en) * | 2018-12-19 | 2019-04-30 | 帕潘纳(北京)科技有限公司 | A kind of heterocyclic carboxylic acid class compound it is decarboxylation method used |
| CN112574095A (en) * | 2020-12-21 | 2021-03-30 | 常州大学 | Novel method for nitrifying isatin derivative |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102603740B (en) | 2014-05-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101219997B (en) | Synthesis of 2-chlorine-5- amido pyrimidine | |
| CN102603740B (en) | Synthetic method of 4-nitro-7-azaindole | |
| CN104926768A (en) | Moslosooflavone, isowogonin and norwogonin synthetic method | |
| CN102491974B (en) | Method for synthesizing 1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-formamidine hydrochloride | |
| CN109867673B (en) | Method for synthesizing palbociclib | |
| CN102321086B (en) | Synthesizing method of adenine | |
| CN105153149A (en) | Preparation method for selective kinases inhibitor Palbociclib | |
| CN104370930A (en) | Method for efficiently preparing di(hetero)arylbenzopyrone/cyclopentanone derivative through rhodium catalysis-based C-H/C-H oxidation coupling reaction | |
| CN103664952B (en) | A kind of preparation method of Zopiclone | |
| CN105418681A (en) | Preparation method of tedizolid phosphate | |
| CN104844593A (en) | Synthetic method for Apixaban drug intermediate | |
| CN113912609B (en) | Preparation method of natural alkaloid tryptanthrin and derivatives thereof | |
| CN104876911A (en) | Simple method for synthesizing delafloxacin | |
| CN102924472B (en) | Preparation method for olanzapine | |
| CN101429117A (en) | Process for producing 2, 4, 6-trichlorobenzoic acid | |
| CN103772282B (en) | A kind of preparation method of the 3-tertiary butyl-1H-pyrazoles-4-formaldehyde | |
| CN101555248B (en) | Method for preparing poly-substituted 1, 5-naphthyridine compound | |
| CN103159641A (en) | Method for preparing intermediate 2-carboxylic acid-5-(2-methyl-benzoylamino)toluene for tolvaptan | |
| CN103408447B (en) | Process for synthesizing flutamide | |
| CN103788084A (en) | Tetrahydroisoquinoline derivative and synthesis method thereof | |
| CN102329237A (en) | Production process of 2-chloro-5-nitrobenzoic acid | |
| CN102531884A (en) | Method for preparing 4-ethoxy phenylacetic acid | |
| CN105273008A (en) | Method and process for synthesizing riboflavin sodium phosphate | |
| CN101880278A (en) | One-step method for synthesizing 2,9-dimethyl-4,7-diphenyl-1,10-phenanthroline | |
| CN105367567B (en) | A kind of compound and its application in the western croak of Leo is prepared |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C56 | Change in the name or address of the patentee | ||
| CP01 | Change in the name or title of a patent holder |
Address after: 210061 Nanjing high tech Industrial Development Zone, Jiangsu Province Road, No. 10 Patentee after: PHARMABLOCK (NANJING) R&D CO., LTD. Address before: 210061 Nanjing high tech Industrial Development Zone, Jiangsu Province Road, No. 10 Patentee before: Nanjing Medical Stone and Medicine Research and Development Co., Ltd. |